Welcome to the international HTA database

Showing [24006 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	WorkSafeBC	Percussion therapy for neuropathic pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2022	National Institute for Health and Care Excellence (NICE)	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NICE technology appraisal guidance 798
2022	NIHR Health Technology Assessment programme	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022	WorkSafeBC	Ketamine infusion therapy for hyperalgesia and or central sensitivity pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating diabetic macular oedema. NICE technology appraisal guidance 799
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating wet age-related macular degeneration. NICE technology appraisal guidance 800
2022	Health Technology Wales (HTW)	Stereotactic ablative radiotherapy (SABR) for the treatment of renal cell carcinoma
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2022	NIHR Health Technology Assessment programme	Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NICE technology appraisal guidance 802
2022	NIHR Health Technology Assessment programme	Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022	NIHR Health Services and Delivery Research programme	Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022	National Institute for Health and Care Excellence (NICE)	Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804
2022	NIHR Health Technology Assessment programme	Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022	National Institute for Health and Care Excellence (NICE)	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. NICE technology appraisal guidance 805
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	National Institute for Health and Care Excellence (NICE)	Belimumab for treating lupus nephritis (terminated appraisal). NICE technology appraisal guidance 806
2022	Scottish Health Technologies Group (SHTG)	Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	WorkSafeBC	Environmental exposure to respirable particles and estimated risk of sarcoidosis
2022	National Institute for Health and Care Excellence (NICE)	Roxadustat for treating symptomatic anaemia in chronic kidney disease. NICE technology appraisal guidance 807
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	Agency for Healthcare Research and Quality (AHRQ)	Acute treatments for episodic migraine
2022	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 808
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	WorkSafeBC	Vision therapy as treatment for traumatic brain injury: 2022 update
2022	National Institute for Health and Care Excellence (NICE)	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease. NICE technology appraisal guidance 809
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022	NIHR Health Services and Delivery Research programme	Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022	Health Technology Wales (HTW)	Laryngeal biopsies in the outpatient setting in people with suspected head and neck dysplasia/cancer
2022	WorkSafeBC	Inpatient versus outpatient programs as treatment for PTSD
2022	National Institute for Health and Care Excellence (NICE)	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. NICE technology appraisal guidance 810
2022	NIHR Health Technology Assessment programme	Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
2022	WorkSafeBC	Oral collagen supplements for shoulder sprain strain
2022	Agency for Healthcare Research and Quality (AHRQ)	Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022	National Institute for Health and Care Excellence (NICE)	Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 811
2022	NIHR Health Technology Assessment programme	REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022	Gesundheit Osterreich GmbH (GOeG)	[Cost effectiveness of communication training for health care professionals]
2022	WorkSafeBC	Convergence insufficiency and COVID-19 infection
2022	National Institute for Health and Care Excellence (NICE)	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812
2022	NIHR Health Technology Assessment programme	Improving the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography (Perfusion CT)
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2022	Malaysian Health Technology Assessment (MaHTAS)	First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022	WorkSafeBC	Lose-dose naltrexone as treatment for post-COVID conditions
2022	National Institute for Health and Care Excellence (NICE)	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022	Scottish Health Technologies Group (SHTG)	vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2022	National Institute for Health and Care Excellence (NICE)	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022	NIHR Health Technology Assessment programme	A proportionate, universal parenting programme to enhance social-emotional well-being in infants and toddlers in England: the E-SEE Steps RCT
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022	National Institute for Health and Care Excellence (NICE)	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022	National Institute for Health and Care Excellence (NICE)	Setmelanotide for treating obesity caused by LEPR or POMC deficiency. NICE highly specialised technologies guidance 21
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022	National Institute for Health and Care Excellence (NICE)	Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over. NICE highly specialised technologies guidance 20
2022	NIHR Health Technology Assessment programme	Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022	Agency for Care Effectiveness (ACE)	Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. NICE technology appraisal guidance 818
2022	National Institute for Health and Care Excellence (NICE)	Elosulfase alfa for treating mucopolysaccharidosis type 4A. NICE highly specialised technologies guidance 19
2022	Agency for Care Effectiveness (ACE)	Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Axicabtagene Ciloleucel (reassessment after the deadline: (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma)]
2022	National Institute for Health and Care Excellence (NICE)	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2022	National Institute for Health and Care Excellence (NICE)	Atidarsagene autotemcel for treating metachromatic leukodystrophy. NICE highly specialised technologies guidance 18
2022	Agency for Care Effectiveness (ACE)	The PrecivityAD test for the prognosis of Alzheimer's disease
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	National Institute for Health and Care Excellence (NICE)	Brolucizumab for treating diabetic macular oedema. NICE technology appraisal guidance 820
2022	National Institute for Health and Care Excellence (NICE)	KardiaMobile for detecting atrial fibrillation. NICE medical technologies guidance 64
2022	National Institute for Health and Care Excellence (NICE)	Odevixibat for treating progressive familial intrahepatic cholestasis. NICE highly specialised technologies guidance 17
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022	Agency for Care Effectiveness (ACE)	Artificial intelligence and its clinical applications
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	National Institute for Health and Care Excellence (NICE)	Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2022	Agency for Care Effectiveness (ACE)	3D printing and its clinical applications
2022	National Institute for Health and Care Excellence (NICE)	Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal). NICE technology appraisal guidance 822
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022	Agency for Care Effectiveness (ACE)	Overview of clinical applications of telemedicine
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]